← brief for 2026-09-30 · Slowing decline

Targeting biglycan-TLR2/TLR4 interaction with synthetic peptides mitigates inflammation and ameliorates renal function in ischemia-reperfusion injury.

Key takeaways

Researchers tested a new treatment for kidney injury in animals and cells. It helped reduce inflammation and improve kidney function. This was not tested in people yet.

Who did this work

Merline R (Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.) · Hsieh LT (Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.) · Zeng-Brouwers J (Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.) · Vutukuri R (Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.) · Briggs DC (Signalling and Structural Biology Laboratory, The Francis Crick Institute, London, UK.) · Day AJ (Manchester Cell-Matrix Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.) · Wygrecka M (Center for Infections and Genomics of the Lung (CIGL), Justus Liebig University, Giessen, Germany.) · Nowak S (Department of Biophysics, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.) · Bartoszewski R (Department of Biophysics, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland.) · Schaefer L (Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany. [email protected].)

Source

Article · Europe PMC, CKD · 2026-09-25
https://doi.org/10.1186/s11658-026-01019-2